Aggrenox®

Endothelium

ER-DP: Benefits Beyond Platelet Inhibition

ER-DP: Benefits Beyond Platelet Inhibition

Extended-release dipyridamole (ER-DP)

  • Enhances the antithrombotic and anti-atherosclerosis effect on the vessel wall once available in sufficiently high plasma concentrations (i.e. it may restore endothelial dysfunction caused by vascular disease)
  • DP is poorly solubilised in conditions of reduced gastric acidity frequently found in elderly patients or patients taking gastric acid suppressant medication
  • The extended-release formulation provides reliable plasma concentrations
  • The ASA dose in ER-DP is sufficient to block platelet aggregation

References

Eisert WG. in Platelets (Academic Press) 2002: 803-815.
Van der Maelen C. Neurology 2002, 58: A312.
Eisert WG. Am J Ther 2001, 8: 443-449.
PubMed Abstract
Weyrich et al. P134. ESC 2003.
Eisert WG. Neurology 2001, 57: S20-S23.
PubMed Abstract
Serebruany V. Am J Hematology 2003, 72: 280-281.
PubMed Abstract
Aktas et al. Stroke 2003, 34: 764-769
PubMed Abstract
Malinin A. HeartDrug 2002, 2: 93-104.
Abstract
Biaggioni I. J Investig Med 2003, 51: S370.

previous 1|2|3|4